Abstract. The present study analyzed the mRNA expression levels of genes involved in the transport and metabolism of methotrexate (MTX) (RFC1, ABCC1, ABCB1, GGH, FPGS, ATIC, TS, MTHFR, MTRR, MS and MTHFD1) in patients with acute leukemia (AL). The expression levels of the examined genes were analyzed by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in patients with AL (ALL:50/AML:19) and 66 healthy individuals. The mRNA expression levels of RFC1, MS, MTRR, MTHFR and ABCB1 were decreased (P<0.05), while those of GGH, FPGS, TS and MTHFD1 (P<0.05) were overexpressed in patients with AL. Patients with high mRNA levels of GGH (OR=4.28, 95% CI=1.29-14.14), TS (OR=7.14, 95% CI 1.84-27.81), MTHFR (OR=4.81, 95% CI=1.31-17.64), ABCB1 (OR=4.61, 95% CI=1.33-15.97) and ABCC1 (OR=5.50, 95% CI=1.12-27.06) had a higher chance of relapse. Interestingly, high mRNA levels of RFC1 are a protective factor in the risk of AL relapse (OR=0.22, 95% 0.06-0.80). The results of the present study indicated that deregulation of folate pathway gene expression is associated with poor prognosis in AL and that the expression levels of these markers could serve as novel molecular targets for the treatment of patients with AL.
Introduction
Leukemia is the most common childhood cancer. Mexico has one of the highest incidences of childhood leukemia in the world and has significantly higher mortality rates for this disease than do other developed nations (1) . Moreover, acute lymphoblastic leukemia (ALL) is the most common; the second most frequent type of leukemia in childhood is acute myeloid leukemia (AML) (2, 3) .
Methotrexate (MTX) is currently one of the most widely prescribed drugs for the treatment of ALL (4, 5) . MTX is a folic acid antagonist, and its efficacy as an antineoplastic treatment is largely attributed to its high affinity for blocking the synthesis of purines and pyrimidines by inhibiting key enzymes (6) .
MTX is predominantly transported to the interior of the cell by the reduced folate carrier (RFC/SLC19A1) (7); upon entry into the cell, MTX undergoes polyglutamylation [active methotrexate polyglutamate (MTXPG)], and 2 to 6 glutamate residues are added by folylpolyglutamate synthetase (FPGS) (7, 8) . The main targets of MTXPG are dihydrofolate reductase (DHFR-also inhibited by MTX monoglutamates), thymidylate synthase (TS), 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC) and several enzymes involved in de novo purine synthesis (8) . Alternatively, the polyglutamation process competes with deconjugation that converts MTXPG back into MTX by gamma-glutamyl hydrolase (GGH) (8) , which increases the efflux of MTX by the efflux transporters of the ATP-binding cassette (ABC) superfamily, including ABCC1 and ABCG2 (7, 9, 10) .
Alterations in the transport and metabolism of MTX result in a decrease in its cellular accumulation, and this decrease has been associated with resistance to MTX and compromises its healing effect. MTX resistance has been attributed to downregulation of the RFC gene as well as increased levels of DHFR and TS enzymes (7, 9, 11, 12) . However, there are a limited number of studies on the function of the expression levels of genes involved in the transport and metabolism of MTX in patients with childhood acute leukemia (AL). In this study, we analyzed the mRNA expression levels of genes involved in the transport and metabolism of MTX [reduced folate carrier (RFC1), ATP-binding cassette subfamily C member 1 (ABCC1), ATP-binding cassette subfamily B member 1 (ABCB1), gamma-glutamyl hydrolase (GGH), folylpolyglutamate synthetase (FPGS), 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC), thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), methionine transferase reductase (MTRR), methionine synthase (MS) and methylenetetrahydrofolate dehydrogenase (MTHFD1)] in patients with AL; additionally, weanalyzed whether the expression levels of these mRNAs could be used as prognostic markers in AL. (13) and Organista-Nava J et al (14) . Controls included 66 healthy individuals (4-10x10 3 leukocytes/mm 3 ) without a family history of leukemia. In the present study, subjects in both groups, including both genders, were 1-18 years of age and were residents of the State of Guerrero, Mexico. Informed consent was obtained from all individuals or their guardians after a detailed briefing of the study aims. The present study and informed consent procedure were approved by the Institutional Review Board of the Cancer Institute of the State of Guerrero, Mexico. Overall survival (OS) and risk classification were defined according to previous reports (13, 14) . Briefly, OS time was determined as the time between the day of registration into the study and the day of mortality (from any cause) or the day of last known contact. Relapse or lack of response was defined as recurrence of lymphoblasts of >20% blast cells in the marrow or localized leukemic infiltrates at any site (15) . Patients with AL were classified into one of the following two groups: Low-risk, aged between 1 and 10 years with <50,000 leucocytes/mm 3 at diagnosis; and High-risk, aged <1 and >10 years with >50,000 leucocytes/mm 3 at diagnosis (13) .
Materials and methods

Study population.
Specimen collection and total RNA extraction. Bone marrow and/or blood samples were taken from the 135 participants and placed in tubes with an anticoagulant (EDTA). Leukocytes were purified by selective osmotic lysis. Briefly, 1 ml of whole blood or 250 l of bone marrow was added to 4 ml of Red Blood Cell (RBC) Lysis Solution (155 mM ammonium chloride, 10 mM potassium bicarbonate, 0.1 mM EDTA, pH 7.4). The sample was mixed and incubated for 15 min on ice and was mixed every 5 min by pipetting; the samples were then centrifuged for 10 min at 2,000 rpm to 4˚C to remove the RBC lysis buffer. Total RNA from leukocytes was extracted according to Chomczynski and Sacchi (16) .
cDNA synthesis. Total RNA (500 ng) was reverse transcribed into cDNA by priming with oligo (dT , and SYBR Green I dye, as well as 10 mM of each primer, 500 ng of the template and ultrapure water. All primer sequences and product sizes are described in Table I . PCRs were processed through 40 cycles of a 3-step PCR, including 15 sec of denaturation at 95˚C, a 60-sec primer-dependent annealing phase [60 or 61˚C, and according to previous reports (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , Table I ], and 60 sec of template-dependent elongation at 72˚C.
The expression levels of mRNAs were determined from the threshold cycle (Ct), and the relative expression levels were calculated using the 2 -∆∆Ct method (28) . For mRNA quantification, Ct values were normalized to the expression level of hypoxanthine-guanine phosphoribosyltransferase (HPRT) mRNA.
Detection of translocations.
The detection of BCR-ABL, ETV6 RUNX1, AML1-ETO and CBFΒ-MYH11 translocations was realized according to the report by Organista-Nava et al (14) .
Statistical analysis. Continuous data are presented as the means ± standard deviations (SDs) or the medians and 25 and 75th interquartiles. Categorical data were compared by Chi-square or Fisher's exact tests. The Mann-whitney test was used for comparison of the differences in mRNA expression levels between the groups. P-values less than 0.05 were considered statistically significant. Statistical analyses of all data were performed using SPSS software, v.20.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism software (v.5.0; GraphPad Software, Inc., La Jolla, CA, USA). Table IV) . were highly expressed in the AL patients with relapse. As shown in Fig. 2 and Table IV, Table IV) expression levels between AL patients with relapse and AL patients without relapse.
Results
Population
Folate pathway gene expression is associated with AL relapse. To evaluate the correlation between mRNA expression and the risk of relapse to AL, patients were divided into low expression and high expression groups. The media expression levels of RFC1 (0.76-fold), GGH (1.93-fold), FPGS (3.21-fold), TS (9.42-fold), ATIC (1.60-fold), MTHFR (0.56-fold), MTHFD1 (2.60-fold), MTRR (0.64-fold), MS (1.20-fold), ABCB1 (0.62-fold) and ABCC1 (1.10-fold) were used as cut-off points to divide patients with AL into two groups (Table III) . Patients with expression lower than the cut-off value were considered to be in the low expression group [RFC1 (n=31), GGH (n=30), FPGS (n=31), TS (n=36), ATIC (n=35), MTHFR (n=27), MTHFD1 (n=30), MTRR (n=34), MS (n=35), ABCB1 (n=36) and ABCC1 (n=39)], while patients with expression higher than the cut-off value were considered to be in the high expression group [RFC1 (n=30), GGH (n=33), FPGS (n=32), TS (n=33), ATIC (n=34), MTHFR (n=32), MTHFD1 (n=30), MTRR (n=30), MS (n=29), ABCB1 (n=33) and ABCC1 (n=24)]. Table V ). In contrast, high mRNA levels of RFC1 had a protective effect (OR=0.22; CI95% 0.06-0.80; P=0.021).
The following variables were included in a multivariate analysis: Risk by age and leukocytes at diagnosis and the expression levels of RFC1, GGH, TS, MTHFR ABCB1 and ABCC1 mRNA, to determine whether the mRNA expression of each gene predicts the risk of relapse independently. It was observed that the expression levels of RFC1, GGH, TS, MTHFR ABCB1 and ABCC1 were independent prognostic factors in AL patients (Table V) . These data suggest that the mRNA expression levels of folate pathway genes could play an important role in the risk of relapse in this disease.
Poor survival based on the mRNA expression levels of folate pathway genes. The association between the mRNA expression levels of folate pathway genes and the survival of patients with AL was investigated. In this analysis, patients with high expression levels of GGH mRNA tended to have lower survival than did those with low expression levels of GGH mRNA (log-rank test, P=0.004; Fig. 3B ). Similarly, a difference in survival was evident among individuals with high levels of MTHFD1 mRNA (log-rank test; P=0.035; Fig. 3G ). In patients with AL, kaplan-Meier analysis showed no significance between survival and the mRNA levels of RFC1, FGS, TS, ATIC, MTHFR, MTRR, MS, ABCB1, and ABCC1 (log-rank test; P>0.05; Fig. 3 ).
Discussion
ALs are the most common type of childhood cancer. Despite advancements in therapeutic strategies, the prognosis of (29) . Therefore, finding new biomarkers for the identification of patients with a high risk of not responding to treatment is very important to modify therapeutic methods to improve the survival of patients with AL. MTX was one of the first anticancer therapeutic agents for the treatment of childhood leukemia (4, 6) . In this study, the expression of RFC1 was significantly lower (P= 0.006) in patients with AL with relapse than in those without relapse. According to previous studies, the expression levels of RFC1 mRNA are diminished in HEP-2 cells treated with MTX, and reduced RFC1 leads to decreased intracellular MTX, which is involved in MTX resistance (30, 31) . Thus, the decreased expression of RFC1 mRNA results in inefficient absorption of antifolates by tumor cells, leading to the development of MTX resistance.
Alternatively, the mRNA expression levels of MTXmetabolizing enzymes, including FPGS and GGH, were elevated in patients with AL, while GGH mRNA was overexpressed in patients who relapsed during treatment with MTX. GGH is responsible for eliminating the glutamate groups from MTXPG, favoring its efflux from cells, and high levels of GGH mRNA are reportedly associated with resistance to MTX (32). Our results are consistent with those of kim et al (33) , who reported that overexpression of GGH is associated with MTX resistance. These results suggest that GGH is related to MTX resistance in patients with AL since its overexpression could favor the exit of MTX from the cell, preventing it from exerting its antineoplastic activity. Similarly, GGH expression is associated with poor prognosis and unfavorable clinical outcomes in breast and prostate cancers and pleural mesothelioma (18, 34, 35) . Consistent with these findings, our data suggest that high mRNA levels of GGH play an important role in survival in patients with AL and that GGH may be a therapeutic target in AL. Additionally, FPGS mRNA was overexpressed in patients with AL with relapse. Similar to previous reports, the expression of FPGS was elevated in AL cell lines (36) .
Regarding folate-dependent enzymes, changes were observed in the mRNA expression levels of the MS, MTRR, MTHFR, TS, MTHFD1 and ATIC genes. MTRR is involved in the synthesis of DNA and production of S-adenosylmethionine (SAM); MTRR also plays an important role in carcinogenesis (37) . MTRR is an enzyme that controls the activity of MS in the metabolism of folate through the transfer of methyl groups of methyltetrahydrofolate to homocysteine via MS (24, 37, 38) . No studies have analyzed the expression of MTTR mRNA in patients with AL. In our study, MTRR expression levels were lower in the AL group than in the control group. Nevertheless, significant differences were not observed between patients with and without relapse. In patients with breast cancer and ovarian cancer cells, increased expression of MTRR mRNA (37,39) was observed. MS catalyzes the remethylation of homocysteine to methionine; deficiencies in the activity of MS result in hyperhomocysteinemia (25, 40) , which is a risk factor for cancer (41) . This decrease in MS activity leads to an increase in homocysteine and a reduction in DNA methylation processes and, is an important factor in the development of cancer (42, 43) . Our results show decreased levels of MS in patients with AL, similar to the findings in ovarian, renal, prostate, breast, colon, leukemia, non-small cell lung carcinoma cell lines (44) .
Another important enzyme involved in the remethylation of homocysteine is MTHFR, which catalyzes the conversion of 5,10-CH 3 -THF to 5-CH 3 -THF for the remethylation of homocysteine to methionine (22, 45) . In this study, MTHFR mRNA levels were decreased in patients with AL. we also observed that MTHFR mRNA levels were substantially elevated in patients who relapsed during treatment compared to those in patients who did not relapse. This observation is similar to the findings of Liu et al (22) , who observed that the reduced mRNA level of MTHFR had an association with the risk for esophageal cancer. The biological effect of overexpression of MTHFR mRNA is not completely defined, and there are no studies showing its relationship with response to treatment in patients with AL.
TS is a folate-dependent enzyme that plays a central role in deoxythymidine monophosphate synthesis, which is critical for the synthesis and repair of DNA by serving as the main intracellular source of dUTM (46, 47) . Our results show increased levels of TS mRNA in patients with AL, similar to findings observed in breast cancer (47) and pancreatic cancer (20) . we also found that patients with AL with relapse showed increased mRNA expression levels of TS. Our results are in line with previous reports showing a significant aggressive phenotype and poor prognosis (47) (48) (49) . These data indicate that TS is involved in disease progression and relapse in cancer, which occur because TS is a target enzyme of MTXPG and is overexpressed in AL and in patients with relapse. It is possible that MTX does not inhibit this enzyme, as we did not observe inhibition of TS; thus, DNA synthesis is favored, and cells continue to proliferate uncontrollably.
The ABC transporter family is a group of membrane transporters that transport different molecules through the cell membrane. ABCs are divided into different subgroups (named A-G) and have been associated with multidrug resistance (26, 50, 51) . Regarding the ABC transporter family, we found increased expression levels of ABCB1 and ABCC1 mRNAs in patients with AL who relapsed during treatment. Our findings are similar to those reported by Ho et al (52) and Eadie et al (53) , who observed that the overexpression of ABC transporter mRNA (ABCB1, ABCC1 and ABCG2) is correlated with increased cellular resistance of leukemic cells.
Likewise, in a multivariate analysis, we observed that the expression levels of RFC1, GGH, TS, MTHFR ABCB1 and 
relapse n (%) relapse n (%) P-value ABCC1 are independent prognostic factors in AL patients, excluding leukocytes at diagnosis and age (Table V) . As shown in Fig. 4 , we hypothesize that the high expression levels of ABCB1 and ABCC1 genes play an important role in the resistance to MTX treatment by favoring its efflux from cells. Likewise, decreased levels of RFC1 mRNA will result in MTX not being captured by the cells. In additon, the increase in GGH levels favors the depolyglutamation of MTX, preventing it from exerting its activity. ATIC and TS are overexpressed, indicating that MTXPG does not inhibit these enzymes and, favors cell proliferation in AL patients with relapse (Fig. 4) .
In conclusion, our data indicate that the deregulation of the mRNA expression levels of genes involved in the transport (RFC1, ABCB1, and ABCC1) and metabolism (GGH, TS, MTHFR) of MTX had impacts on the risk of relapse and survival of AL Mexican patients. However, this analysis was based only on 69 patients and needs to be confirmed in a larger population.
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